Drugs / BI 3720931
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06962852 | May 2025 → Oct 2040 expected | cystic fibrosis | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06515002 | Nov 2024 → Feb 2026 | cystic fibrosis | Boehringer Ingelheim | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 3720931 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06962852 ↗ |
| Route | Inhaled | “an Inhaled Lentiviral Vector Gene Therapy” NCT06962852 ↗ |